Startups
Synthesize Bio
Synthesize Bio develops generative genomics foundation models that predict human tissue and cell responses to drugs, diseases and experimental conditions. Its GEM models generate bulk and single-cell RNA-sequencing data from natural-language experiment descriptions, supporting virtual patient cohorts, biomarker research, safety analysis and clinical trial design. The company works with biotech and pharmaceutical teams to extend limited datasets and test development decisions before expensive studies. Its outputs support research and internal decision-making; the company states that they cannot currently serve as primary evidence in regulatory submissions.
Founded 2023